Skip to main content

Support for the UN Sustainable Development Goals

Across our value chain CSL’s activities support the achievement of the United Nations Sustainable Development goals, in particular:

 Sustainable Development Goal  CSL's position and contribution

Good Health and Well Being SD Goal Icon

CSL develops and delivers innovative medicines that save lives, protect public health and help people with life-threatening medical conditions live full lives. CSL holds more than 1,000 product registrations (including varying vial sizes) in 103 countries, supporting newborns through to the elderly. Our support for patient groups and their programs helps to raise awareness and diagnosis of rare and serious diseases, improve access to our life-saving therapies and protect public health.

More information available in CSL’s Annual Report on pages 24-36 and 54-60.

Quality Education SD Goal Icon

Across our facilities, CSL actively supports the placement of interns and/or graduates. For example, CSL Behring Australia and Seqirus Australia’s graduate program of four years has seen more than 45 graduates progress through two year rotations in highly specialised areas. In addition, we are committed to advancing women’s education and opportunities in science, technology, engineering and mathematics (STEM) careers. A key element of CSL’s global talent strategies is our relationships with schools at both the secondary and university levels as well as professional diversity organisations. We met our goal of forming and/or deepening our strategic relationships in all major markets. Our biomedical recognition and award programs encourage the best and brightest to pursue higher education in STEM and further their research outcomes.

More information available in CSL’s Annual Report on pages 50-54 and 56.

Gender Equality SD Goal Icon

CSL strives to create an open and trusting work environment characterised by equal opportunity, as well as a diverse, inclusive, collaborative and values-based culture. We rely on our people’s unique perspectives, ideas, capabilities and experiences to deliver for our business, our patients and our shareholders. We believe diversity and inclusion are crucial to strong business growth and performance.

More information available in CSL’s Annual Reporton page 50 and CSL’s 2021 Corporate Governance Statement.

Decent Work and Economic Growth SD Goal Icon

We employ over 25,000 people worldwide representing 39 different nationalities. We promote safety, health and wellbeing in the workplace and strive to equip our people with the right skills to perform their roles. We provide development initiatives and opportunities and recognise the contribution of employees to our business success. In 2018/19 we introduced a new capability – supply chain integrity. Once matured, the capability will ensure and demonstrate that CSL’s supply chain partners are conducting their business to a standard aligned to CSL’s Code of Responsible Business Practice (CRBP) and supply chain transparency and modern slavery legislation.

More information available in CSL’s Annual Report on pages 38, 43, 50-53.

Industry Innovation and Infrastructure

Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise, thereby ensuring our continued growth. We enter into collaborative partnerships to further the science and prospects for successful product development. These partnerships often result in shared knowledge, intellectual property or products. For example, in Australia, as at 31 March 2020, there were 72 active research and development collaboration and licensing agreements.

More information available in CSL’s Annual Report on page 29.

Responsible Consumption and Production

CSL has an Environment, Health, Safety and Sustainability (EHS2) plan to ensure our facilities operate to industry and regulatory standards. This plan includes compliance with government regulations and commitments to continuously improve the health and safety of the workforce as well as minimising the impact of operations on the environment. We actively monitor our waste management practices as part of our business operations and environmental management efforts.

More information available in CSL’s Annual Report on pages 39-42.

Climate Action SD Goal Icon

Detailed climate change risk assessments are carried out following CSL’s Risk Framework. Risk assessments are based on identification, quantification and mitigation of risks which would prevent or impair CSL from meeting its business objectives. These assessments were undertaken in 2008/09. 2014/15, and will be repeated when a new international consensus on climate change physical and transitional risks emerges, notably through the Intergovernmental Panel on Climate Change (IPCC) process. The latest narrow-based risk assessment undertaken in 2019/20. The report identified some potential risks across 10-30 year timelines related to cooling systems, flood zones, allergen loads, heat stress and transport disruptions over that time. These findings were not considered unique to CSL nor to have a high impact but do provide management potential planning and design opportunities for future plasma centre site selection and centre expansion planning, and ongoing opportunities to engage with third party suppliers on the impacts of climate change as part of the third party due diligence processes.

More information available in CSL’s Annual Report on page 39.